13F Holdings
中文EN

ANIK Anika Therapeutics, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 898437 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY52.5%
TTM net income YoY94.7%
TTM EPS YoY94.3%
Revenue 3-yr CAGR-8.9%
Net income 3-yr CAGR—

Margins

Gross margin63.4%
Operating margin-2.1%
Net margin-1.4%
FCF margin1.9%
EBITDA margin2.5%

Returns

ROE-1.2%
ROA-0.9%
ROIC (approx.)-2.3%
Asset turnover0.65x

Leverage & solvency

Liabilities / assets27.4%
Debt / equity0.00x
Current ratio3.86x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-4.24x
Accruals ratio-4.9%
Payout ratio—
Capex / revenue4.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$112.82M$119.91M$120.79M$113.83M$147.79M
Cost of revenue$49.01M$43.91M$38.26M$40.61M$64.85M
Gross profit$63.81M$76.00M$82.53M$73.22M$82.94M
R&D expense$25.77M$25.54M$21.76M$18.32M$27.33M
SG&A expense$49.09M$55.55M$59.92M$51.23M$74.10M
Operating income-$11.05M-$5.10M$844,000$3.67M$2.62M
Pretax income-$9.31M-$2.76M$3.16M$4.32M$2.43M
Income tax$672,000$6.06M$6.59M$2.12M-$1.71M
Net income-$10.88M-$56.38M-$82.67M-$14.86M$4.13M
EBITDA-$5.68M$1.78M$7.28M$10.37M$9.10M
EPS (basic)-0.76-3.83-5.64-1.020.29
EPS (diluted)-0.76-3.83-5.64-1.020.28
Weighted avg. shares (diluted)14.34M14.72M14.66M14.79M14.63M
Balance sheet
Cash & equivalents$57.48M$55.63M$68.74M$86.33M$94.39M
Short-term investments$23.69M$23.59M$26.36M$34.63M$29.84M
Receivables$23.69M$23.59M$26.36M$34.63M$29.84M
Inventory$18.79M$23.81M$24.43M$39.77M$36.01M
Current assets$103.36M$113.65M$163.31M$169.55M$168.53M
PP&E, net$40.32M$38.99M$37.45M$48.28M$47.60M
Goodwill$8.05M$7.12M$7.57M$7.34M$7.78M
Intangibles$1.65M$2.49M$2.58M$74.60M$82.38M
Total assets$190.27M$202.74M$270.63M$349.13M$347.54M
Current liabilities$21.91M$23.31M$31.06M$27.91M$29.80M
Total liabilities$46.80M$48.75M$58.37M$63.56M$60.45M
Shareholders' equity$143.47M$153.99M$212.26M$285.56M$287.08M
Shares outstanding13.89M14.42M14.66M14.62M14.44M
Cash flow statement
Operating cash flow$11.19M$5.40M-$1.79M$4.41M$8.40M
Capital expenditure$6.83M$7.73M$5.43M$7.49M$5.14M
Free cash flow$4.36M-$2.33M-$7.21M-$3.08M$3.25M
Investing cash flow-$401,000-$8.33M-$5.43M-$7.49M-$3.12M
Financing cash flow-$10.55M-$12.73M-$6.32M-$4.85M-$6.78M
Depreciation & amortization$5.37M$6.88M$6.43M$6.70M$6.48M
Stock-based compensation$10.08M$13.13M$15.24M$14.31M$11.09M
Share buybacks$9.48M$10.91M$5.00M$0$0

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.